Statera BioPharma (NASDAQ:STAB) Shares Up 3.7%

Statera BioPharma Inc (NASDAQ:STAB) shot up 3.7% on Friday . The stock traded as high as $2.02 and last traded at $1.97. 76,350 shares traded hands during trading, a decline of 34% from the average session volume of 115,065 shares. The stock had previously closed at $1.90.

The business has a 50-day moving average of $2.66. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.31 and a current ratio of 1.31.

Statera BioPharma (NASDAQ:STAB) last issued its earnings results on Monday, November 15th. The company reported ($0.47) earnings per share (EPS) for the quarter. The business had revenue of $0.24 million for the quarter.

Several large investors have recently modified their holdings of STAB. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Statera BioPharma during the 3rd quarter valued at $28,000. Dowling & Yahnke LLC acquired a new stake in shares of Statera BioPharma during the 3rd quarter valued at $34,000. BlackRock Inc. acquired a new stake in shares of Statera BioPharma during the 3rd quarter valued at $44,000. UBS Group AG acquired a new stake in shares of Statera BioPharma during the 3rd quarter valued at $45,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Statera BioPharma during the 3rd quarter valued at $166,000. 3.80% of the stock is owned by institutional investors.

Statera BioPharma Company Profile (NASDAQ:STAB)

Statera Biopharma, Inc is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia.

Further Reading: What is a Stop Order?

Receive News & Ratings for Statera BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Statera BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.